Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kw-2478 Free Base SCHEMBL29617983 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| Kw-2478 Free Base SCHEMBL29349763 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| Kw-2478 Free Base SCHEMBL2862975 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| SCHEMBL2858330 | 0.97 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| SCHEMBL2860015 | 0.96 | CYP2D6 (0.46) | SMN1; SMN2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL18539209 | 0.95 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| SCHEMBL2856184 | 0.94 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| SCHEMBL2871431 | 0.94 | KMT2A (0.47) | SMN1; SMN2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL2864939 | 0.93 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP2D6CYP2C9SLC5A7MEN1 | |
| SCHEMBL2858292 | 0.92 | MCHR1 (0.45) | SMN1; SMN2SLC5A7MEN1KMT2ATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382903-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-07-12 | — | — | US | claimed |
| US-20190151326-A1 | CANCER THERAPY | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2019-05-23 | — | — | US | claimed |
| US-20190038610-A1 | CANCER THERAPY | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2019-02-07 | — | — | US | claimed |
| WO-2014018862-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A HEAT SHOCK PROTEIN INHIBITOR AND A|PURINE DE NOVO SYNTHESIS INHIBITOR FOR TREATING RHEUMATOID ARTHRITIS OR CANCER | CORNING INCORPORATED (US) | 2014-01-30 | — | — | WO | claimed |
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | Rubedo Life Sciences, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | Rubedo Life Sciences, Inc. | 2023-05-04 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100104567-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2133095-A1 | PHARMACEUTICAL COMPOSITION | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382903-B2 | Cancer therapy | DHODH, MCL1, DOHH | SMN1; SMN2 4328/4885CYP2D6 702/4885CYP2C9 1454/4885 |
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | SMN1; SMN2 4682/4885CYP2D6 1825/4885CYP2C9 1162/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | SMN1; SMN2 4682/4885CYP2D6 1825/4885CYP2C9 1162/4885 |
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | AGER, SENP6, SENP3 | SMN1; SMN2 1269/4885CYP2D6 3316/4885CYP2C9 4404/4885 |
| US-20190038610-A1 | CANCER THERAPY | DHODH, MCL1, DOHH | SMN1; SMN2 4328/4885CYP2D6 702/4885CYP2C9 1454/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | SMN1; SMN2 4676/4885CYP2D6 4369/4885CYP2C9 4584/4885 |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | SENP3, SENP6, SENP1 | SMN1; SMN2 1363/4885CYP2D6 4282/4885CYP2C9 4540/4885 |
| US-20190151326-A1 | CANCER THERAPY | DHODH, MCL1, DOHH | SMN1; SMN2 4328/4885CYP2D6 702/4885CYP2C9 1454/4885 |
| US-20100104567-A1 | PHARMACEUTICAL COMPOSITION | FLT4, FLT3, FLT1 | SMN1; SMN2 4485/4885CYP2D6 248/4885CYP2C9 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.